Zhixia Wang1, William L Woolverton. 1. Department of Psychiatry, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS 39216, USA.
Abstract
RATIONALE: (+/-)3,4-Methylenedioxymethamphetamine (MDMA) is an analog of methamphetamine (MA) and a drug of abuse. MA, MDMA, and its isomers release monoamine neurotransmitters with varying selectivities and would, therefore, be predicted to vary in their relative strength as reinforcers. OBJECTIVES: This study compared self-administration of MA, MDMA, and its isomers using a progressive-ratio schedule in rhesus monkeys. METHODS: Rhesus monkeys [n = 6, MA and MDMA; n = 5, (+)-MDMA and (-)-MDMA] were prepared with chronic i.v. catheters and allowed to self-administer cocaine or saline in daily baseline sessions. When responding was stable, MA (0.006-0.1 mg/kg per injection), MDMA (0.025-0.8 mg/kg injection), (+)-MDMA (0.025-0.8 mg/kg per injection), or (-)-MDMA (0.05-0.8 mg/kg per injection) was made available in test sessions. RESULTS: MA, MDMA, and (+)-MDMA functioned as positive reinforcers in all monkeys with a potency relationship of MA > (+)-MDMA > (+/-)-MDMA. Two of five monkeys took (-)-MDMA above saline levels. Dose-response relationships were biphasic for MA and (+/-)-MDMA, and asymptotic for (+)-MDMA. In terms of maximum number of injection per session, a measure of relative reinforcing strength, the order was MA > (+)-MDMA = (+/-)-MDMA > (-)-MDMA. CONCLUSIONS: MDMA and (+)-MDMA were consistent positive reinforcers, but weaker than MA, whereas (-)-MDMA was, at best, a weak reinforcer in some monkeys. The reinforcing strength of MDMA appears to derive primarily from (+)-MDMA. Because MDMA and its isomers have been shown to have relatively higher serotonin to dopamine releasing potency, these data support the hypothesis that increasing 5-HT releasing potency relative to DA is associated with weaker reinforcing effects.
RATIONALE: (+/-)3,4-Methylenedioxymethamphetamine (MDMA) is an analog of methamphetamine (MA) and a drug of abuse. MA, MDMA, and its isomers release monoamine neurotransmitters with varying selectivities and would, therefore, be predicted to vary in their relative strength as reinforcers. OBJECTIVES: This study compared self-administration of MA, MDMA, and its isomers using a progressive-ratio schedule in rhesus monkeys. METHODS:Rhesus monkeys [n = 6, MA and MDMA; n = 5, (+)-MDMA and (-)-MDMA] were prepared with chronic i.v. catheters and allowed to self-administer cocaine or saline in daily baseline sessions. When responding was stable, MA (0.006-0.1 mg/kg per injection), MDMA (0.025-0.8 mg/kg injection), (+)-MDMA (0.025-0.8 mg/kg per injection), or (-)-MDMA (0.05-0.8 mg/kg per injection) was made available in test sessions. RESULTS: MA, MDMA, and (+)-MDMA functioned as positive reinforcers in all monkeys with a potency relationship of MA > (+)-MDMA > (+/-)-MDMA. Two of five monkeys took (-)-MDMA above saline levels. Dose-response relationships were biphasic for MA and (+/-)-MDMA, and asymptotic for (+)-MDMA. In terms of maximum number of injection per session, a measure of relative reinforcing strength, the order was MA > (+)-MDMA = (+/-)-MDMA > (-)-MDMA. CONCLUSIONS:MDMA and (+)-MDMA were consistent positive reinforcers, but weaker than MA, whereas (-)-MDMA was, at best, a weak reinforcer in some monkeys. The reinforcing strength of MDMA appears to derive primarily from (+)-MDMA. Because MDMA and its isomers have been shown to have relatively higher serotonin to dopamine releasing potency, these data support the hypothesis that increasing 5-HT releasing potency relative to DA is associated with weaker reinforcing effects.
Authors: Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth Journal: Mol Pharmacol Date: 2003-06 Impact factor: 4.436
Authors: Joshua A Lile; Zhixia Wang; William L Woolverton; Jessica E France; Timothy C Gregg; Huw M L Davies; Michael A Nader Journal: J Pharmacol Exp Ther Date: 2003-09-03 Impact factor: 4.030
Authors: Ryan A Gregg; Michael H Baumann; John S Partilla; Julie S Bonano; Alexandre Vouga; Christopher S Tallarida; Venkata Velvadapu; Garry R Smith; M Melissa Peet; Allen B Reitz; S Stevens Negus; Scott M Rawls Journal: Br J Pharmacol Date: 2014-12-15 Impact factor: 8.739
Authors: S L Huskinson; J E Naylor; E A Townsend; J K Rowlett; B E Blough; K B Freeman Journal: Psychopharmacology (Berl) Date: 2016-11-28 Impact factor: 4.530
Authors: Alexandre Vouga; Ryan A Gregg; Maryah Haidery; Anita Ramnath; Hassan K Al-Hassani; Christopher S Tallarida; David Grizzanti; Robert B Raffa; Garry R Smith; Allen B Reitz; Scott M Rawls Journal: Neuropharmacology Date: 2014-12-09 Impact factor: 5.250